IL-6 Receptor anticorps

N° du produit ABIN1383672

Cité dans 9 publications. Cet anticorps anti-IL-6 Receptor Monoclonal Souris (Clone B-R6) (ABIN1383672) détecte spécifiquement IL-6 Receptor dans IHC, IP, ELISA, FACS et Func. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour IL-6 Receptor anticorps (ABIN1383672)

Antigène: IL-6 Receptor (IL6R) (Interleukin 6 Receptor (IL6R))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp IL-6 Receptor est non-conjugé

Application: Immunohistochemistry (IHC), Immunoprecipitation (IP), ELISA, Flow Cytometry (FACS), Functional Studies (Func)

Clone: B-R6

Détail du produit anti-IL-6 Receptor anticorps

Specificité: Recognises the Interleukin-6 Ra subunit, IL-6 Ra, IL-6 R, a 80 kDa protein

Purification: Ion exchange chromatography

Stérilité: 0.22 μm filtered

Immunogène: gp80 transfected CHO cell line,Myeloma X63/AG.8653 x Balb/c spleen cells

Isotype: IgG1 kappa

Biological Activity Comment: Inhibits IL-6 induced proliferation of XG-1 cells

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Phosphate-buffered saline. Sterile-filtered through 0.22 μm. Carrier and preservative free

Agent conservateur: Without preservative

Stock: 4 °C

Stockage commentaire: Stable at +2-8°C for 12 months. For longer storage freeze aliquots.

Références pour anticorps anti-IL-6 Receptor (ABIN1383672)

Burger, Guenther, Bakker, Schmalzing, Bernand, Baum, Duerr, Hocke, Steininger, Gebhart, Gramatzki: "Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma." dans: The hematology journal : the official journal of the European Haematology Association / EHA, Vol. 2, Issue 1, pp. 42-53, (2002) (PubMed).

Menetrier-Caux, Thomachot, Alberti, Montmain, Blay: "IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells." dans: Cancer research, Vol. 61, Issue 7, pp. 3096-104, (2001) (PubMed).

Kube, Holtick, Vockerodt, Ahmadi, Haier, Behrmann, Heinrich, Diehl, Tesch: "STAT3 is constitutively activated in Hodgkin cell lines." dans: Blood, Vol. 98, Issue 3, pp. 762-70, (2001) (PubMed).

Gu, De Vos, Rebouissou, Jourdan, Zhang, Rossi, Wijdenes, Klein: "Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors." dans: Leukemia, Vol. 14, Issue 1, pp. 188-97, (2000) (PubMed).

Menetrier-Caux, Montmain, Dieu, Bain, Favrot, Caux, Blay: "Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor." dans: Blood, Vol. 92, Issue 12, pp. 4778-91, (1999) (PubMed).

Dubois, Barthélémy, Durand, Liu, Caux, Brière: "Toward a role of dendritic cells in the germinal center reaction: triggering of B cell proliferation and isotype switching." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 162, Issue 6, pp. 3428-36, (1999) (PubMed).

Dubois, Massacrier, Vanbervliet, Fayette, Brière, Banchereau, Caux: "Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 161, Issue 5, pp. 2223-31, (1998) (PubMed).

Larregina, Morelli, Kolkowski, Sanjuan, Barboza, Fainboim: "Pattern of cytokine receptors expressed by human dendritic cells migrated from dermal explants." dans: Immunology, Vol. 91, Issue 2, pp. 303-13, (1997) (PubMed).

Müller-Newen, Köhne, Keul, Hemmann, Müller-Esterl, Wijdenes, Brakenhoff, Hart, Heinrich: "Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing." dans: European journal of biochemistry / FEBS, Vol. 236, Issue 3, pp. 837-42, (1996) (PubMed).

Détails sur IL-6 Receptor

Antigène: IL-6 Receptor (IL6R) (Interleukin 6 Receptor (IL6R))

Autre désignation: CD126

Sujet: IL-6R / gp80

Poids moléculaire: 80 kDa

Pathways: Signalistation JAK/STAT, Autophagy, Growth Factor Binding, Cancer Immune Checkpoints